BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 11900797)

  • 1. Mu-opioid receptor down-regulation and tolerance are not equally dependent upon G-protein signaling.
    Gomes BA; Shen J; Stafford K; Patel M; Yoburn BC
    Pharmacol Biochem Behav; 2002 May; 72(1-2):273-8. PubMed ID: 11900797
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of G(i)alpha2-protein in opioid tolerance and mu-opioid receptor downregulation in vivo.
    Yoburn BC; Gomes BA; Rajashekara V; Patel C; Patel M
    Synapse; 2003 Feb; 47(2):109-16. PubMed ID: 12454948
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of cAMP-dependent protein kinase (PKA) in opioid agonist-induced mu-opioid receptor downregulation and tolerance in mice.
    Shen J; Benedict Gomes A; Gallagher A; Stafford K; Yoburn BC
    Synapse; 2000 Dec; 38(3):322-7. PubMed ID: 11020235
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Opioid agonist efficacy predicts the magnitude of tolerance and the regulation of mu-opioid receptors and dynamin-2.
    Pawar M; Kumar P; Sunkaraneni S; Sirohi S; Walker EA; Yoburn BC
    Eur J Pharmacol; 2007 Jun; 563(1-3):92-101. PubMed ID: 17349996
    [TBL] [Abstract][Full Text] [Related]  

  • 5. mu-Opioid receptor downregulation contributes to opioid tolerance in vivo.
    Stafford K; Gomes AB; Shen J; Yoburn BC
    Pharmacol Biochem Behav; 2001; 69(1-2):233-7. PubMed ID: 11420091
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Opioid agonists differentially regulate mu-opioid receptors and trafficking proteins in vivo.
    Patel MB; Patel CN; Rajashekara V; Yoburn BC
    Mol Pharmacol; 2002 Dec; 62(6):1464-70. PubMed ID: 12435815
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Continuous opioid agonist treatment dose-dependently regulates mu-opioid receptors and dynamin-2 in mouse spinal cord.
    Zhang Q; Purohit V; Yoburn BC
    Synapse; 2005 Jun; 56(3):123-8. PubMed ID: 15765525
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Opioid agonist and antagonist treatment differentially regulates immunoreactive mu-opioid receptors and dynamin-2 in vivo.
    Yoburn BC; Purohit V; Patel K; Zhang Q
    Eur J Pharmacol; 2004 Sep; 498(1-3):87-96. PubMed ID: 15363980
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ultra-low dose naloxone restores the antinociceptive effect of morphine in pertussis toxin-treated rats by reversing the coupling of mu-opioid receptors from Gs-protein to coupling to Gi-protein.
    Tsai RY; Tai YH; Tzeng JI; Cherng CH; Yeh CC; Wong CS
    Neuroscience; 2009 Dec; 164(2):435-43. PubMed ID: 19682558
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vivo regulation of mu-opioid receptor density and gene expression in CXBK and outbred Swiss Webster mice.
    Duttaroy A; Yoburn BC
    Synapse; 2000 Aug; 37(2):118-24. PubMed ID: 10881033
    [TBL] [Abstract][Full Text] [Related]  

  • 11. mu-Opioid receptor internalization-dependent and -independent mechanisms of the development of tolerance to mu-opioid receptor agonists: Comparison between etorphine and morphine.
    Narita M; Suzuki M; Narita M; Niikura K; Nakamura A; Miyatake M; Yajima Y; Suzuki T
    Neuroscience; 2006; 138(2):609-19. PubMed ID: 16417975
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Opioid receptor regulation in mice.
    Yoburn BC; Billings B; Duttaroy A
    J Pharmacol Exp Ther; 1993 Apr; 265(1):314-20. PubMed ID: 8386239
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [(35)S]GTPγS binding and opioid tolerance and efficacy in mouse spinal cord.
    Madia PA; Navani DM; Yoburn BC
    Pharmacol Biochem Behav; 2012 Mar; 101(1):155-65. PubMed ID: 22108651
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Continuous intrathecal opioid treatment abolishes the regulatory effects of magnesium and guanine nucleotides on mu opioid receptor binding in rat spinal membranes.
    Wong CS; Su YF; Watkins WD; Chang KJ
    J Pharmacol Exp Ther; 1992 Jul; 262(1):317-26. PubMed ID: 1320689
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Supersensitivity to mu-opioid receptor-mediated inhibition of the adenylyl cyclase pathway involves pertussis toxin-resistant Galpha protein subunits.
    Mostany R; Díaz A; Valdizán EM; Rodríguez-Muñoz M; Garzón J; Hurlé MA
    Neuropharmacology; 2008 May; 54(6):989-97. PubMed ID: 18384820
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vivo homologous regulation of mu-opioid receptor gene expression in the mouse.
    Sehba F; Duttaroy A; Shah S; Chen B; Carroll J; Yoburn BC
    Eur J Pharmacol; 1997 Nov; 339(1):33-41. PubMed ID: 9450614
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Magnitude of tolerance to fentanyl is independent of mu-opioid receptor density.
    Chan KW; Duttory A; Yoburn BC
    Eur J Pharmacol; 1997 Jan; 319(2-3):225-8. PubMed ID: 9042594
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Spinal interaction between the highly selective μ agonist DAMGO and several δ opioid receptor ligands in naive and morphine-tolerant mice.
    Szentirmay AK; Király KP; Lenkey N; Lackó E; Al-Khrasani M; Friedmann T; Timár J; Gyarmati S; Tóth G; Fürst S; Riba P
    Brain Res Bull; 2013 Jan; 90():66-71. PubMed ID: 22995282
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Region-dependent attenuation of mu opioid receptor-mediated G-protein activation in mouse CNS as a function of morphine tolerance.
    Sim-Selley LJ; Scoggins KL; Cassidy MP; Smith LA; Dewey WL; Smith FL; Selley DE
    Br J Pharmacol; 2007 Aug; 151(8):1324-33. PubMed ID: 17572699
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Endogenous regulator of g protein signaling proteins reduce {mu}-opioid receptor desensitization and down-regulation and adenylyl cyclase tolerance in C6 cells.
    Clark MJ; Traynor JR
    J Pharmacol Exp Ther; 2005 Feb; 312(2):809-15. PubMed ID: 15383633
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.